ArticleEvolutionary applications2020
Migratory hosts can maintain the high-dose/refuge effect in a structured host-parasite system: The case of sea lice and salmon.
Article in Evolutionary applications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Article
- Modelling the Effectiveness of Gene-Edited Salmon at Sea Lice Control and the Use of Refugia to Mitigate Counter-Adaptation.Evolutionary applications · 2025Article
- Threshold-based disease treatment approach modulates economic, conservation and evolutionary trade-offs in sea louse-salmon aquaculture system.Theoretical ecology · 2025Article
- Evolutionary predictions for a parasite metapopulation: Modelling salmon louse resistance to pest controls in aquaculture.Evolutionary applications · 2023Article
- Applying genetic technologies to combat infectious diseases in aquaculture.Reviews in aquaculture · 2023Review
- Salmon lice in the Pacific Ocean show evidence of evolved resistance to parasiticide treatment.Scientific reports · 2022Article
- Losing the 'arms race': multiresistant salmon lice are dispersed throughout the North Atlantic Ocean.Royal Society open science · 2021Article
- Migratory hosts can maintain the high-dose/refuge effect in a structured host-parasite system: The case of sea lice and salmon.Evolutionary applications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migration can reduce parasite burdens in migratory hosts, but it connects populations and can drive disease dynamics in domestic species. Farmed salmon are infested by sea louse parasites, often carried by migratory wild salmonids, resulting in a costly problem for industry and risk to wild populations when farms amplify louse numbers. Chemical treatment can control lice, but resistance has evolved in many salmon-farming regions. Resistance has, however, been slow to evolve in the north-east Pacific Ocean, where large wild-salmon populations harbour large sea louse populations. Using a mathematical model of host-macroparasite dynamics, we explored the roles of domestic, wild oceanic and connective migratory host populations in maintaining treatment susceptibility in associated sea lice. Our results show that a large wild salmon population, unexposed to direct infestation by lice from farms; high levels of on-farm treatment; and a healthy migratory host population are all critical to slowing or stopping the evolution of treatment resistance. Our results reproduce the "high-dose/refuge effect," from the agricultural literature, with the added requirement of a migratory host population to maintain treatment susceptibility. This work highlights the role that migratory hosts may play in shared wildlife/livestock disease, where evolution can occur in ecological time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.